My watch list  

Pamidronic acid

Pamidronic acid
Systematic (IUPAC) name
(3-amino-1-hydroxy-1-phosphono-propyl)phosphonic acid
CAS number 40391-99-9
ATC code M05BA03
PubChem 4674
DrugBank APRD01161
Chemical data
Formula C3H11NO7P2 
Mol. mass 235.07 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding 54%
Metabolism Nil
Half life 28 ± 7 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

B3(AU) D(US)

Legal status

POM(UK) -only(US)

Routes Intravenous

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia®, is a bisphosphonate.



It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels.


Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.

Side effects

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[1]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.


  1. ^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73-5. PMID 16369966.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pamidronic_acid". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE